Monthly Archives: February 2014
First Treatment for MPS IVA Approved
BioMarin Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Vimizim™ (elosulfase alfa), the first specific therapy approved for the treatment of Morquio A (MPS IVA syndrome.)
Annual EveryLife Art Contest
Calling All Rare Artists! The Annual EveryLife Art Contest has moved to Facebook to allow you to share your art with friends and to enable the community to vote and …
BioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome
FDA NEWS RELEASE FDA approves Vimizim to treat rare congenital enzyme disorder First drug to receive Rare Pediatric Disease Priority Review Voucher The U.S. Food and Drug Administration today approved …
Rare Disease Day 2014
What is Rare Disease Day? Click here to find out!
BioMarin Announces Selection of NAGLU, BMN 250 for the Treatment of Sanfilippo B
BioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B (MPS IIIB) Please click here for the full BioMarin News Release
40 Years of Achievements Gala Invitation
The National MPS Society cordially invites you to join us in celebrating 40 years of achievements through honoring the heroes of MPS research, innovation, advocacy, and courage.
Emory “All LSD” meeting on March 8, 2014
Click HERE for more information about the “All LSD” patient meeting about research being held on March 8, 2014 at the Emory Conference Center in Atlanta, GA. Patients, parents, and …